Contribution and Interaction of Shiga Toxin Genes to Escherichia coli O157:H7 Virulence

Toxins (Basel). 2019 Oct 18;11(10):607. doi: 10.3390/toxins11100607.

Abstract

Escherichia coli O157:H7 is the predominant cause of diarrhea-associated hemolytic uremic syndrome (HUS) worldwide. Its cardinal virulence traits are Shiga toxins, which are encoded by stx genes, the most common of which are stx1a, stx2a, and stx2c. The toxins these genes encode differ in their in vitro and experimental phenotypes, but the human population-level impact of these differences is poorly understood. Using Shiga toxin-encoding bacteriophage insertion typing and real-time polymerase chain reaction, we genotyped isolates from 936 E. coli O157:H7 cases and verified HUS status via chart review. We compared the HUS risk between isolates with stx2a and those with stx2a and another gene and estimated additive interaction of the stx genes. Adjusted for age and symptoms, the HUS incidence of E. coli O157:H7 containing stx2a alone was 4.4% greater (95% confidence interval (CI) -0.3%, 9.1%) than when it occurred with stx1a. When stx1a and stx2a occur together, the risk of HUS was 27.1% lower (95% CI -87.8%, -2.3%) than would be expected if interaction were not present. At the population level, temporal or geographic shifts toward these genotypes should be monitored, and stx genotype may be an important consideration in clinically predicting HUS among E. coli O157:H7 cases.

Keywords: Escherichia coli O157:H7; Shiga toxin-producing Escherichia coli; hemolytic uremic syndrome; stx genes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Escherichia coli Infections / microbiology*
  • Escherichia coli Infections / therapy
  • Escherichia coli O157 / genetics*
  • Escherichia coli O157 / isolation & purification
  • Escherichia coli O157 / pathogenicity
  • Genotype
  • Hemolytic-Uremic Syndrome / microbiology*
  • Hemolytic-Uremic Syndrome / therapy
  • Humans
  • Middle Aged
  • Renal Replacement Therapy
  • Risk
  • Shiga Toxin / genetics*
  • Virulence / genetics*
  • Young Adult

Substances

  • Shiga Toxin